Table 1 The characteristics of included studies
Author | Year | Local | Sample size | Age# of intervention group | Age of Control group | Abbreviations | Intervention | Control | Follow-up |
|---|---|---|---|---|---|---|---|---|---|
Bhatt [28] | 2019 | Multination | 8179 | 64 (57–69) | 64 (57–69) | REDUCE-IT | EPA | Placebo | 4.9 Years |
Ouchi [29] | 2019 | Japan | 1046 | 80.6 ± 4.7 | 80.6 ± 4.7 | EWTOPIA 75 | Ezetimibe | Control | 5 Years |
Elam [30] | 2016 | US,Canada | 3635 | 62.3 ± 6.8 | 62.3 ± 6.8 | ACCORD | Fenofibrate | Placebo | 4.7 Years |
Arbel [31] | 2016 | Israel | 458 | 58 ± 7 | 58 ± 7 | BIP | Bezafibrate | Placebo | 20 Years |
Kalil [32] | 2015 | US | 3413 | 70.8 ± 7.4 | 70.6 ± 7.2 | AIM-HIGH | Niacin | Placebo | 4.1 Years |
Landray [33] | 2014 | UK,Scandinavia,China | 6575 | 64.9 ± 7.5 | 64.9 ± 7.5 | HPS2-THRIVE | Niacin plus laropiprant | Placebo | 3.9 Years |
Davidson [34] | 2014 | US | 676 | 61 () | 61 (?) | FIRST | Fenofibrate | Placebo | 108 Weeks |
The ORIGIN Trial Investigators [35] | 2012 | Canada | 4270 | 63.5 ± 7.8 | 63.6 ± 7.9 | ORIGIN | Omega-3 fatty acid | Placebo | 6.2 Years |
Amarenco [36] | 2008 | Multinational | 1575 | 63.0 ± 0.2 | 62.5 ± 0.2 | SPARCL | Atorvastatin | Placebo | 4.9 Years |
Yokoyama [37] | 2007 | Japan | 9211 | 61 ± 8 | 61 ± 9 | JELIS | EPA | Control | 5 Years |
The FIELD study investigators [38] | 2005 | Multinations | 5093 | 62.2 ± 6.9 | 62.2 ± 6.8 | FIELD | Fenofibrate | Placebo | 5 Years |
Colhoun [39] | 2004 | UK, Ireland | 1425 | 61.8 ± 8.0 | 61.5 ± 8.3 | CARDS | Atorvastatin | Placebo | 4 Years |
Sasaki [40] | 2002 | Japan | 497 | 55.5 ± 10.2 | 55.5 ± 10.1 | NA | Pravastatin | Control | 5 Years |
Ballantyne [41] | 2001 | Multinations | 458 | 57.7 ± 7.8 | 57.7 ± 7.8 | 4S | Simvastatin | Placebo | 5.4 Years |
Durrington [42] | 2000 | UK | 59 | 55.2 ± 7.0 | 54.8 ± 10.2 | NA | Omega-3 fatty acid | Placebo | 1 Year |
Rubins [43] | 1999 | US | 1185 | 64 ± 7 | 64 ± 7 | VA-HIT | Gemfibrozil | Placebo | 5.1 Years |
Tonkin [44] | 1998 | Australia, New Zealand | 1490 | 62 (55–67) | 62 (55–68) | LIPID | Pravastatin | Placebo | 6.1 Years |
Sacks [45] | 1996 | US, Canada | 2079 | 59 ± 9 | 59 ± 9 | CARE | Pravastatin | Placebo | 5 Years |
Shepherd [46] | 1995 | UK | 3356 | 55.3 ± 5.5 | 55.1 ± 5.5 | WSCPS | Pravastatin | Placebo | 4.9 Years |
Carlson [47] | 1988 | Sweden | 301 | Males 59.2 ± 0.4 Female 63.0 ± 0.7 | Male 58.9 ± 0.4 Females 62.5 ± 0.9 | SIHDSPS | Niacin plus Clofibrate | Control | 5 Years |
Manninen [48] | 1988 | Finland | 1490 | NA (40–55) | NA (40–55) | HHS | Gemfibrozil | Placebo | 5 Years |